Caliper Life Sciences Grants Multi-Year Imaging Patent License
News Aug 13, 2007
Non-invasive optical imaging allows scientists to visualize, track and quantify biological processes at the molecular level in living animals with high throughput and relatively low cost.
Caliper can provide commercial and academic customers with a selection of in vivo offerings including imaging systems, reagents, applications, proprietary methods and services that improve drug discovery and development efforts.
"This multi-year agreement further validates the importance and relevance of Caliper's optical imaging technology and intellectual property," said Kevin Hrusovsky, chief executive officer, Caliper Life Sciences.
"More than 70% of major pharmaceutical companies, and 60% of major biotech companies, now hold a license to the Caliper Optical Imaging Patent Suite, and smaller biotechs are following suit in increasing numbers."
Hrusovsky added, "Our recent notification of allowance of patent claims for conjugate fluorescence imaging methods from the U.S. Patent and Trademark Office has significantly increased the value of Caliper's intellectual property estate and complements Caliper's aggressive investment in conjugate probe development."
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Researchers Identify Druggable Genomic Targets in Malaria ParasiteNews
Using whole-genome analysis and chemogenomics, scientists have discovered novel antimalarial drug targets and drug-resistance genes. The researchers analyzed >250 Plasmodium falciparum cell lines, which were resistant to 37 different anti-malarial compounds.READ MORE